Enlivex Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
0.570
-0.011 (-1.81%)
At close: Jun 26, 2026, 4:00 PM EDT
0.571
+0.001 (0.18%)
After-hours: Jun 26, 2026, 7:54 PM EDT
Enlivex Employees
Enlivex had 34 employees as of December 31, 2025. The number of employees decreased by 37 or -52.11% compared to the previous year.
Employees
34
Change
-37
Growth
-52.11%
Revenue / Employee
n/a
Profits / Employee
$36,339,059
Market Cap
137.40M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 34 | -37 | -52.11% |
| Dec 31, 2021 | 71 | 21 | 42.00% |
| Dec 31, 2020 | 50 | 14 | 38.89% |
| Dec 31, 2019 | 36 | 5 | 16.13% |
| Dec 31, 2018 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ADC Therapeutics | 193 |
| Molecular Partners AG | 134 |
| Agenus | 81 |
| Alpha Cognition | 71 |
| Connect Biopharma Holdings | 64 |
| Jyong Biotech | 27 |
| Genelux | 26 |
| Spero Therapeutics | 25 |
ENLV News
- 4 days ago - Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume - GlobeNewsWire
- 6 days ago - Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion - GlobeNewsWire
- 13 days ago - Enlivex Therapeutics announces issuance of Australian patent - TheFly
- 13 days ago - Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis - GlobeNewsWire
- 26 days ago - ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026 - GlobeNewsWire
- 27 days ago - Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026 - GlobeNewsWire
- 4 weeks ago - Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board - GlobeNewsWire
- 4 weeks ago - Enlivex comments on $100M commitment to Rain’s prediction market - TheFly